Dermatology
Case Report
Vasculitis Occurring during Leflunomide TherapyHolm E.A.a · Balslev E.b · Jemec G.B.E.aaDepartment of Medicine, Division of Dermatology, and bDepartment of Pathology, Roskilde Hospital, Denmark
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: November 07, 2001
Issue release date: 2001
Number of Print Pages: 2
Number of Figures: 2
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
Leflunomide has recently been introduced for systemic treatment of rheumatoid arthritis. It has both immunosuppressive effects and anti-inflammatory properties. We report a patient treated with leflunomide who developed vasculitis as an adverse side effect. As far as we are aware, this is the first published report of vasculitis associated with leflunomide therapy.
© 2001 S. Karger AG, Basel
Related Articles:
References
-
Clinical Pharmacology Online, Leflunomide (Arava), Description, Mechanism of Action, Pharmacokinetics. http://www.imc.gsm.com (14. July 2000).
- Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542–2550.
-
Litt J. Z, Pawlak W: Drug eruption reference manual. Carnforth, Parthenon Publishing Group, 1997; p 509.
-
Habif TP: Clinical Dermatology. A Color Guide to Diagnosis and Therapy, ed 3. St Louis, Mosby, 1995; pp 566–596.
-
Gross WL, Trabandt A, Reinhold-Keller E: Diagnosis and evaluation of vasculitis. Rheumatology (Oxford) 2000;39:245–252.
External Resources
Article / Publication Details
Published online: November 07, 2001
Issue release date: 2001
Number of Print Pages: 2
Number of Figures: 2
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
